BioSpace News Archive

Shares of AVEO Oncology are climbing fast in premarket trading after the company released data that showed positive overall survival benefits of tivozanib in patients with highly refractory metastatic renal cell carcinoma who have received prior immunotherapy treatments.

The results of the two long-term trials showed that patients receiving the company’s checkpoint inhibitor, Opdivo (nivolumab), had a long-term overall survival improvement compared to docetaxel chemotherapy alone.

Polarean Imaging plc, the medical-imaging technology company, with a proprietary drug-device combination product for the magnetic resonance imaging market, announces that further to the announcement of 5 June 2019, the Company has delivered and installed its latest 9820 Xenon Polariser system at the Hospital for Sick Children in Toronto www.sickkids.ca.

Futura Medical plc is pleased to announce a joint venture collaboration with CBDerma Technology Limited to explore the application of Futura’s advanced proprietary transdermal drug delivery technology, DermaSys® for delivery of Cannabidiol.

ProBioGen AG announced the closing of a license agreement with Bayer AG for the GlymaxX® Technology.

Researchers with the Salk Institute combined two separate analytical techniques to analyze how epigenetics affects certain types of brain cells.

Pratteln, Switzerland, September 10, 2019 – Santhera Pharmaceuticals announces the online publication of Phase I data with its human neutrophil elastase inhibitor POL6014 in the Journal of Cystic Fibrosis.

Pneumagen Ltd announced in vivo data on its lead product, Neumifil™, generated from its proprietary GlycoTarge platform.

Oncimmune Holdings plc welcomes the presentation of data by Professor Frank Sullivan (Chief Investigator on the ECLS trial) which has demonstrated the potential of Oncimmune’s EarlyCDT® Lung test to reduce the incidence of patients with late-stage lung cancer at diagnosis, compared with standard clinical diagnosis.

Bactiguard’s indwelling urinary catheters are now approved for reimbursement in the Netherlands, which means that healthcare providers in the home care market can provide patients with Bactiguard’s products for infection prevention and improve their quality of life.